Articles on
Gladly it was a really Good Thursday as stocks finally closed above 4,000 for the first time. This sparks the natural next question of...Is this a breakout or fake out?, asks Steve Reitmeister, editor of Reitmeister Total Return.
Steve Reitmeister
MARKETS
Just about a year ago, I noted that corporate insiders were betting heavily on a reversal in the relative downtrend in value versus growth, recalls Jesse Felder of The Felder Report.
Jesse Felder
MARKETS
Here’s a break down of the Archegos Capital Management liquidation situation from Jason Bodner and Lucas Downey of Mapsignals.com.
Jason Bodner
TECHNICAL
Tickers: MA
Uber Technologies (UBER) carries our highest investment ranking of 5- STARS, or Strong Buy; this opinion reflects our view of growth prospects ahead, suggests analyst Angelo Zino in CFRA Research's flagship newsletter, The Outlook.
Angelo Zino
TECHNOLOGY
Tickers: UBER
I have one new pick this week, the hardware kingpin on the new remote world: Logitech International S.A. (LOGI), one of the largest makers of peripherals for the PC and mobile phone market, observes Tony Sagami, growth stock specialist and editor of Ultimate Portfolio.
Tony Sagami
TECHNOLOGY
Tickers: LOGI
Since adding telecom giant AT&T (T) to our Income Portfolio in 2014, it has steadily paid out high dividends like clockwork. However, its share price gradually diminished as the company took on debt to finance expensive acquisitions, observes Jim Pearce, chief investment strategist at Investing Daily's Personal Finance.
James Pearce
TELECOM
Tickers: T
Osisko Gold Royalties Ltd. (OR) is an intermediate precious metals royalty company. OR’s cornerstone asset is a 5% net smelter return (NSR) royalty on the Canadian Malartic mine, Canada’s largest gold mine, explains Peter Krauth, editor of Resource Maven's Gold Resource Investor.
Peter Krauth
COMMODITIES
Tickers: OR
Why do 90% of traders lose money? You might have heard this, “90% of traders lose 90% of their money in the first 90 days of trading.” This is known as the 90/90/90 rule. I don’t even know if this is true, but it seems that a lot of traders are losing money, states Markus Heitkoetter of Rockwell Trading.
Markus Heitkoetter
TOOLS
Lululemon once again beat earnings maintaining its perfect record of exceeding market expectations for the past two years, explains Boris Schlossberg of BK Asset Management.
Boris Schlossberg
CONSUMER
Tickers: LULU
Sponsored Content - Passed as part of the Tax Cuts and Jobs Act in 2017, Opportunity Zones can help stimulate economic growth in over 8700 identified, distressed communities across the US, says Chris Loeffler, CEO & co-founder, Caliber.
Chris Loeffler
TAXES
$139.00
2:01:44
$139.00
2:00:31
$139.00
1:57:53
$139.00
1:15:36
Virtual Learning
Join Jay Hatfield for this in-depth session, designed to bring you the latest intelligence available so you can identify and profit from the opportunities in today's markets. Positioning portfolios with exposure to income strategies is critical in today's market environment. Jay Hatfield will review the outlook for interest rates and the credit cycle, investments that seek consistent performance with low volatility, and investment opportunities in preferred stocks.
Jay Hatfield
INCOME
34:50
Despite the rapid growth in responsible investing, many investors still believe they have to sacrifice returns to make a positive impact. This session will put that myth to rest by explaining what responsible investing is, why it matters, and how to choose the best approach for managing your responsible investments.
Anthony Eames
STRATEGIES
48:41
You can outperform any ETF or index by selecting the best stocks in that ETF or index. The Buffett and Beyond Clean Surplus Finance model has outperformed the S&P 500 by almost 3 to 1 on a compounded basis since 2003. When this methodology is applied to ETFs, we can outperform almost all industry and index ETFs. Over a 5-year period, Buffett and Beyond model portfolios have outperformed some ETFs by as much as a 3 to 1 margin. If you want to differentiate yourselves in the ETF marketplace, this is the strategy for you.
Joseph Belmonte
STRATEGIES
32:19
The Incentive Profit Sharing Accounts achieved an outsized return of 230% in less than one year since their inception in April 2020 compared to the S&P 500 TR of 47%. The AFC Growth Accounts are besting the S&P 500 TR by a compounded average of 3% annually for the last 16 years. The presentation will explore why higher returns may NOT mean higher risk. These are actual client accounts net of all fees and costs. These accounts are not models, not hypothetical, not back-tested. Mike Adams will discuss both the structure of the accounts and superior stock selection. The accounts are always fully invested. It's a great feeling to be caught with your pants up!' as Peter Lynch said. We always have to say that past performance is no guarantee of future performance.
Mike Adams
TOOLS
32:37
In this presentation you will learn a simple yet effective way to read charts in order to profit. Latoya Smith, co-founder of The Profit Room, will walk you through market structure on various time frames which will reveal high favorable risk/reward ratios. You will also be able to apply these concepts to any market such as stocks, options, forex, futures, etc.
Latoya Smith
TOOLS
31:57
Starting a trading career isn't a decision to be taken lightly. It is possible to be successful and earn a living trading only a few hours per day, but that's likely many months away for people just starting out.
Join Oliver Velez, bestselling author, world renowned speaker, and the industry's number one rated educator, to discuss what you need to do in order to put yourself on the right path and jump start your trading career.
Oliver Velez
TRADING
49:21
The recent GameStop squeeze play was fast, furious, and super aggressive. A grand slam for sure. But the problem is, this kind of setup doesn't come along often enough to provide a steady stream of trading income. While waiting for the next GameStop, we need slower and more manageable income strategies to keep us going. We need singles and doubles every week.
In his presentation, Matt Choi, CMT, will demo an options strategy that will get you on base all the time. Singles and doubles if you will. After this 45-minute class, you'll be able to take a big swing and start trading his strategy right away. This is a must-have for serious options traders.
Matt Choi, CMT
OPTIONS
48:45
Good Earth Organics (GEO), a leading manufacturer and producer of certified organic soil and soil amendments specially formulated for cannabis and hemp, will present its public investment opportunity. Liz Wald, the company's chief strategy and digital officer, will discuss the trends in the cannabis market, the US legislative and legalization roadmap, and why investments in ancillary, aka "non-plant-touching" companies like GEO, are delivering outsized returns. She will also discuss GEO's growth strategy, expected uses of funds, and its plans to do a direct OTC listing immediately following its Regulation A capital raise. Be sure to stick around in GEO's Virtual Booth after the live presentation for a Q&A session.
Liz Wald
PRE IPO
28:02
Zhittya Genesis Medicine, Inc., is developing novel pharmaceuticals that have the potential to treat and reverse diseases that account for more than 50% of all adult deaths, worldwide. In FDA-authorized clinical trials these drugs have shown remarkable success in reversing severe coronary artery disease and healing chronic diabetic foot ulcers. New clinical trials are planned in the coming year to treat patients with Parkinson's disease, ALS (Lou Gehrig's disease), multiple sclerosis, chronic stroke, and Alzheimer's disease. A very attractive Pre-IPO investment is now being offered to suitable investors to help fund the upcoming IPO, which has a firm commitment from a highly regarded securities firm and will take place in 5-6 months.
Jack Jacobs
PRE IPO
30:39
Many experts say we're in the golden age of biotechnology, with this sector presenting tremendous opportunities for investors. While Pre-IPO opportunities are traditionally reserved for institutional funds, now you can get in on the ground-floor of this biotech company working to halt and perhaps even reverse disease progression in people living with debilitating diseases with no cures, such as multiple sclerosis and Parkinson's disease, and rare diseases including systemic sclerosis and Huntington's disease—for which it has Orphan Designation—through the convergence of biology, science, and cannabinoids. Join Dr. Jim DeMesa as he provides further insight into this unique investment opportunity.
Jim DeMesa
BIOTECH
31:21
